BPC-157, or pentadecapeptide, is categorized as a body protection compound. It is composed of 15 amino acids in a very particular sequence that doesn’t exist naturally.
It is artificially synthesized in laboratories using the partial sequence of the body-protecting compounds isolated from gastric juices. Hence, it is one of the derivatives of the peptide found in human gastric juices.
The therapeutic effects of BPC-157 are exerted through multiple courses of action. One of the most common ways that BPC-157 acts as a therapeutic agent is by carrying out angiogenesis, which is the formation of new blood vessels.
It does this by activating a protein called the “vascular endothelial growth factor” which initiates the formation of new blood vessels. This ensues in the organization of a healthy vascular network which gives BPC-157 its key regenerative and healing properties.
Another mechanism of action of BPC-157 is blocking the inhibitory growth factor called 4-hydroxynonenal, which is a negative modulator of growth. This allows the peptide to carry out effective healing of wounds, especially surrounding tendons.
It can also trigger the tendon cells to produce more receptors which can bind to growth signaling molecules. The purpose of this is to speed up the process of growth and repair.
BPC-157 also optimizes the spread of fibroblasts. Fibroblasts play a key role in collagen synthesis, an essential and abundant structural protein found in the human body.
BPC-157 is also clinically proven to impact the working of neurotransmitters found in the brain. Neurotransmitters such as serotonin, dopamine, and GABA are influenced by the activity of BPC-157, which overall tends to reduce the chances of developing symptoms of depression, stress, and anxiety.
This peptide is also known to trigger nitric oxide (NO) production, which triggers endothelial cells to dilate. Hence, the overall blood pressure drops in the body. It also helps to deal with conditions like hyperkalemia, i.e., high potassium levels.
Reviews
There are no reviews yet.